Search

The conference highlighted the progress made in understanding recent biological, epidemiological and therapeutic advances in dermatology. Here we provide a synopsis of the main research and clinical findings presented at the meeting of the British Association of Dermatologists (BAD) held during 5–8 July 2005, in Glasgow, U.K., drawing attention to the most important advances and summaries. The BAD meeting was held at the Scottish Exhibition and Conference Centre, Glasgow ( Fig. 1 ). The annual dinner was held in the wonderful setting of Stirling Castle, with Dr Robin Graham-Brown as host. [ABSTRACT FROM AUTHOR]

This article focuses on the relationship of exposure to fluorescent light and risk of malignant melanoma. Also there are reports of melanoma occurring in sunbed users and patients treated with PUVA. Researchers therefore, studied the risk of melanoma in relation to fluorescent light and UV lamp exposure in a case/control study of a Scottish population. One hundred and eighty melanoma patients presenting in the years 1979-1984 and 197 control subjects were included in the study. Analysis was by stratum-matched logistic regression for age, sex and city of interview. Melanoma risk was not significantly raised for exposure to fluorescent light at home or at work.

We present a review of 111 patients who were treated over an initial 3-year period with erlotinib. The median treatment time was 68 days and 59% of patients had stopped treatment within the first 3 months. However, 20 patients were on erlotinib for more than 12 months. Performance status and smoking history were the significant prognostic factors. The overall 3-year survival in patients who had never smoked was 26%., (Copyright (c) 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.)